title: Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain.
abstract: Adjuvant chemotherapy is the current standard in the management of patients with localised colon cancer (CC) following curative resection. The use of oxaliplatin plus 5 fluorouracil/leucovorin (FOLFOX) or oxaliplatin plus capecitabine-based (XELOX) regimens, both approved in Europe as adjuvant treatment for stage III CC, has improved prognosis in this stage, but questions on their usefulness in high-risk stage II or elderly CC patients and on the role of some prognostic biomarkers are still pending. In April 2010, a consensus meeting on adjuvant CC treatment based on a revision of the most recent literature was held in Spain. The panel considered the use of adjuvant chemotherapy for high-risk stage II CC patients to be justified. Additionally, the more convenient administration of oral fluoropyrimidines vs. IV continuous infusion 5-FU would make XELOX a more suitable alternative for the patient. A more cautious decision should be taken when prescribing oxaliplatin treatment in patients aged ≥70.
authors.affiliation: Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Vieitez
authors.forename: R
authors.initials: R
authors.lastname: García-Carbonero
authors.forename: J
authors.initials: J
authors.lastname: Aparicio
authors.forename: J
authors.initials: J
authors.lastname: Feliu
authors.forename: E
authors.initials: E
authors.lastname: González-Flores
authors.forename: E
authors.initials: E
authors.lastname: Grande
authors.forename: T
authors.initials: T
authors.lastname: Pérez-Hoyos
authors.forename: A
authors.initials: A
authors.lastname: Salud
authors.forename: E
authors.initials: E
authors.lastname: Torres
authors.forename: M
authors.initials: M
authors.lastname: Valero
authors.forename: M
authors.initials: M
authors.lastname: Valladares-Ayerbes
authors.forename: E
authors.initials: E
authors.lastname: Díaz-Rubio
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant / Q000379:methods; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D010071:Oxaloacetates; D017410:Practice Guidelines as Topic; D013030:Spain
chemical_list: D000276:Adjuvants, Immunologic; D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil
references.citation: Curr Med Res Opin. 2009 Mar;25(3):797-805
references.pmid: 19215190
references.citation: J Clin Oncol. 1999 Aug;17(8):2412-8
references.pmid: 10561304
references.citation: Gastrointest Cancer Res. 2007 Jul;1(4):146-54
references.pmid: 19262703
references.citation: Pharmacoeconomics. 2009;27(7):597-608
references.pmid: 19663530
references.citation: Health Technol Assess. 2006 Nov;10(41):iii-iv, xi-xiv, 1-185
references.pmid: 17049138
references.citation: Clin Colorectal Cancer. 2009 Oct;8(4):192-3
references.pmid: 19822508
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: J Clin Oncol. 2009 Feb 20;27(6):872-7
references.pmid: 19124803
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4569-74
references.pmid: 17876008
references.citation: N Engl J Med. 1990 Feb 8;322(6):352-8
references.pmid: 2300087
references.citation: N Engl J Med. 2003 Jul 17;349(3):247-57
references.pmid: 12867608
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3109-16
references.pmid: 19451431
references.citation: Clin Chem. 2001 Apr;47(4):624-30
references.pmid: 11274010
references.citation: Onkologie. 2009 Nov;32(11):647-52
references.pmid: 19887868
references.citation: Cancer Res. 1998 Nov 15;58(22):5248-57
references.pmid: 9823339
references.citation: J Clin Oncol. 2006 Nov 20;24(33):5313-27
references.pmid: 17060676
references.citation: Clin Drug Investig. 2008;28(10):645-55
references.pmid: 18783303
references.citation: Cancer. 2007 Mar 15;109(6):1082-9
references.pmid: 17265519
references.citation: Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005390
references.pmid: 18646127
references.citation: J Natl Compr Canc Netw. 2010 Feb;8(2):145
references.pmid: 20141674
references.citation: Eur J Health Econ. 2004 Oct;5(3):270-3
references.pmid: 15714348
references.citation: Eur J Cancer. 2010 Mar;46(4):765-81
references.pmid: 20116997
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3219-26
references.pmid: 20498393
references.citation: J Clin Oncol. 2004 Aug 15;22(16):3395-407
references.pmid: 15199087
references.citation: J Clin Oncol. 2011 Jan 1;29(1):17-24
references.pmid: 21098318
references.citation: N Engl J Med. 2005 Jun 30;352(26):2696-704
references.pmid: 15987918
references.citation: J Clin Oncol. 2007 Mar 1;25(7):767-72
references.pmid: 17228023
references.citation: J Clin Oncol. 1999 Nov;17(11):3553-9
references.pmid: 10550154
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1922-3
references.pmid: 18421044
references.citation: Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):103-14
references.pmid: 20384557
references.citation: Clin Ther. 2004 Apr;26(4):579-89
references.pmid: 15189755
references.citation: J Surg Res. 2005 Apr;124(2):169-74
references.pmid: 15820244
references.citation: J Clin Oncol. 2004 Aug 15;22(16):3408-19
references.pmid: 15199089
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2198-204
references.pmid: 17470851
references.citation: Cancer Chemother Pharmacol. 1998;42(4):336-40
references.pmid: 9744780
references.citation: Lancet. 2007 Dec 15;370(9604):2020-9
references.pmid: 18083404
references.citation: N Engl J Med. 2004 Jun 3;350(23):2343-51
references.pmid: 15175436
references.citation: J Clin Oncol. 2007 Jan 1;25(1):102-9
references.pmid: 17194911
references.citation: J Clin Oncol. 2004 May 15;22(10):1797-806
references.pmid: 15067028
references.citation: Clin Colorectal Cancer. 2006 Nov;6(4):278-87
references.pmid: 17241512
references.citation: Ann Oncol. 2008 Feb;19(2):400-2
references.pmid: 18245135
references.citation: Cancer. 2009 Apr 1;115(7):1412-23
references.pmid: 19195048
references.citation: Br J Cancer. 2006 Apr 24;94(8):1122-9
references.pmid: 16622438
references.citation: Oncology. 2007;72(3-4):248-54
references.pmid: 18185019
references.citation: J Clin Oncol. 2002 Oct 1;20(19):3992-8
references.pmid: 12351596
references.citation: Arch Pathol Lab Med. 2000 Jul;124(7):979-94
references.pmid: 10888773